Young plasma transfusion is an intravenous infusion of plasma, the liquid part of blood, from donors in their late teens to twenties, given to older recipients, hoping to shift aspects of aging. Human studies are few, small and short, and no benefit reaches the higher evidence levels. Allergic reactions have appeared in trials of more than one group. Regulators state the product is not approved for aging. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Total calcium | 8.6–10.3 mg/dL (standard reference range) | Safety check: exchange can lower calcium |
| Hemoglobin and platelet count | Hemoglobin 13.5–17.5 g/dL men, 12.0–15.5 g/dL women; platelets 150–450 ×10⁹/L (standard reference range) | Safety check: baseline anemia delayed Oslo treatments |
| Fibrinogen and INR | Fibrinogen 200–400 mg/dL; INR 0.8–1.1 (standard reference range) | Safety check: exchange removes clotting factors; warfarin users need INR tracking |
| Albumin and total protein | Albumin 3.5–5.0 g/dL; total protein 6.0–8.3 g/dL (standard reference range) | Marker expected to change: plasma removal lowered both |
| Immunoglobulins (IgG, IgA, IgM) | IgG 700–1,600 mg/dL; IgA 70–400 mg/dL; IgM 40–230 mg/dL (standard reference range) | Safety check: low IgA flags allergic risk; levels may fall with exchange |
| Epigenetic age (DNA methylation clocks) | No established target; track change from the individual's own baseline | Marker expected to change in trials, though an unvalidated surrogate |
Cadence: Baseline testing before any session; vital signs at every session; biochemistry about every 3 to 6 sessions in the Oslo pilot, then at 4 weeks and every 3 to 6 months after a course (common practice)